I think you should consider the fact that the effects of treatment upon PFS and OS are very strongly correlated. Often PFS is a useful surrogate for OS in randomized trials on patients. So if PFS is this strong on PIII, I doubt OS end point will not be met.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.